ABBOTT LABORATORIES (ABT)
Health Care / Health Care Equipment
S&P 500$90.64
Below average on several measures. Research carefully.
Weak
Score based on 5 of 5 models — high confidence
Is ABBOTT LABORATORIES a Good Investment in 2026?
ABBOTT LABORATORIES (ABT) scores 4.3 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Buffett model rates ABBOTT LABORATORIES as Strong. The Lynch model is the least favorable, rating it Neutral. ABBOTT LABORATORIES currently trades below its estimated fair value of $107, suggesting potential upside. ABBOTT LABORATORIES ranks #750 out of 1126 stocks in the Health Care sector.
This summary is algorithmically generated and is not financial advice.
Key Metrics
Estimated Fair Value
Trading near or slightly below estimated fair value.
Model-based estimate, not a price target.
5-Model Analysis
Each model evaluates this stock from a different angle. Combined, they form the composite score above.
Piotroski
Attractive
6/9
Buffett
Strong
Business quality & competitive moat
Graham
Neutral
83% above fair value
Lynch
Neutral
PEG 3.4 · Stalwart
Greenblatt
Attractive
Top 25% (rank 18%)
Frequently Asked Questions
Is ABBOTT LABORATORIES (ABT) a good investment?
What is ABBOTT LABORATORIES's Piotroski F-Score?
Is ABT overvalued or undervalued?
How does ABT compare to other Health Care stocks?
What do investment models say about ABT?
Similar Stocks
Compare ABT with
Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer